Abstract
The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Annexin A5 / metabolism*
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / blood supply
-
Breast Neoplasms / drug therapy
-
Carbon-Sulfur Lyases / metabolism*
-
Cell Line, Tumor
-
Enzyme Therapy
-
Female
-
Humans
-
Mammary Neoplasms, Animal / blood supply
-
Mammary Neoplasms, Animal / drug therapy*
-
Methanol / analogs & derivatives*
-
Methanol / therapeutic use
-
Mice
-
Mice, SCID
-
Neoplasm Transplantation
-
Organoselenium Compounds / therapeutic use*
-
Prodrugs / metabolism
-
Prodrugs / therapeutic use
-
Selenomethionine / metabolism*
Substances
-
Annexin A5
-
Antineoplastic Agents
-
Organoselenium Compounds
-
Prodrugs
-
methaneselenol
-
Selenomethionine
-
Carbon-Sulfur Lyases
-
L-methionine gamma-lyase
-
Methanol